Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

Work

Year: 2017

Type: article

Abstract: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (N... more

Source: New England Journal of Medicine

Authors: Solange Peters, D. Ross Camidge, Alice T. Shaw, Shirish M. Gadgeel, Jin Seok Ahn +12 more

Institutions: University of Lausanne, University of Colorado Denver, Massachusetts General Hospital, University of Michigan, Sungkyunkwan University +10 more

Language: English

Cites: 14

Cited by: 2,187

Related to: 10

FWCI: 203

Citation percentile (by year/subfield): 100

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

Sustainable Development Goal: Good health and well-being

Open Access status: bronze